NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA, SOUTH AFRICA, NEW ZEALAND, JAPAN OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL
Reference is made to Soft Softox Solutions AS' (the "Company") notice on 14 August 2025 regarding entering into a financing facility with the global investment fund Long State Investments Limited (“Long State”). As commission for the guarantee facility, Long State shall receive an implementation fee of up to 30 million shares in SoftOx.
The board has today resolved to issue 15 million shares in SoftOx as the first tranche of the 30 million share implementation fee, under the agreement. The subscription price was NOK 0,1004, equal to the VWAP of SoftOx’s shares on 13 August 2025. The new share capital following completion of this issue will be NOK 45 108 339,88 divided into 2 255 416 994 shares, each with a par value of NOK 0,02.
Deviation from shareholders' preferential rights
The board of directors has considered the private placement in light of the equal treatment principles under the Norwegian Securities Trading Act and Oslo Børs' Oslo Rule Book II – Membership and Trading Rules and Oslo Børs' Circular no. 2/2014, and is of the opinion that the waiver of the preferential rights inherent in the following private placement is considered necessary in the interest of time and successful completion in order to secure funding of SoftOx. Taking into consideration the time, costs, and expected terms of alternative methods of securing the necessary funding, the board of directors concluded that the completion of the private placements, including the waiver of the preferential rights inherent to the private placements, is in the common interest of the shareholders of SoftOx.
Further, the board assessed whether a subsequent offering should be carried out. As the private placement is limited and considering the cost inherent in a subsequent offering, the board concluded that a subsequent offering shall not be carried out.
For further information, please contact:
Ulrik Spork, COB SoftOx Solutions AS, +45 31 38 83 87
Ingrid Juven, CFO SoftOx Solutions AS, +47 918 76 165
Mail: ir@soft-ox.com
About SoftOx Solutions AS:
SoftOx Solutions AS (ticker: SOFTX) is a clinical-stage pharmaceutical company listed on Euronext Growth Oslo. The company is developing highly effective pan-antimicrobial pharmaceuticals targeting bacteria, viruses, and fungi. The technology is based on extensive research and development in partnership with leading Nordic research institutes.
About Long State;
Long State is an investment company that focuses on growth sectors. It invests in areas including biotechnology, energy, mining, and technology, and has a worldwide presence, with investments in Australia, Canada, the EEA, the UK, and the US.